Cambridge, MA, United States of America

Zachary Shriver

USPTO Granted Patents = 85 


 

Average Co-Inventor Count = 5.3

ph-index = 18

Forward Citations = 897(Granted Patents)


Inventors with similar research interests:


Location History:

  • Boston, MA (US) (2005 - 2010)
  • Cambridge, MA (US) (2003 - 2018)
  • Winchester, MA (US) (2015 - 2024)
  • Waltham, MA (US) (2023 - 2024)

Company Filing History:


Years Active: 2003-2025

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Antibody Molecules
C5AR1
CD138
Interleukin-2
Dengue Virus
APRIL
Drug Conjugates
Influenza Treatment
Binding Polypeptides
Low Molecular Weight Heparin
Amino Acid Copolymer
Modified Glycans
85 patents (USPTO):Explore Patents

Title: Zachary Shriver: Pioneering Innovations in Antibody Development

Introduction

Zachary Shriver, based in Cambridge, MA, is an accomplished inventor recognized for his significant contributions to the field of biotechnology. With an impressive portfolio of 81 patents, he has played a crucial role in the development of innovative therapies and diagnostic tools targeting various health conditions.

Latest Patents

Among his latest inventions are two groundbreaking patents focused on humanized complement 5A receptor 1 antibodies. The first patent, titled "Humanized complement 5A receptor 1 antibodies and methods of use thereof," provides detailed methodologies for treating dysfunctions related to the C5a/C5aR1 axis pathway, including ANCA-associated vasculitis. This patent outlines a method to administer effective amounts of antibodies or encoding nucleic acids to alleviate symptoms associated with this specific dysfunction.

The second patent, "Antibody molecules to C5AR1 and uses thereof," discloses antibody molecules designed to specifically bind to C5aR1. These novel molecules can potentially treat, prevent, and diagnose disorders such as ANCA-vasculitis, offering new hope for patients affected by this condition.

Career Highlights

Zachary Shriver has built his career at eminent institutions like Visterra, Inc. and the Massachusetts Institute of Technology (MIT). His role in these organizations has solidified his position as a leader in biopharmaceutical innovation, particularly in the development of antibody-based therapies.

Collaborations

Throughout his career, Zachary has collaborated with notable professionals, including Ganesh Venkataraman and Ram Sasisekharan. These partnerships have contributed to the advancement of research and development in antibody engineering and therapeutic applications, enhancing the potential impact of his innovations.

Conclusion

In summary, Zachary Shriver is a remarkable innovator whose work on antibodies targeting the C5a receptor represents a significant advance in medical science. His numerous patents and collaborations with leading experts underscore his commitment to improving patient outcomes through cutting-edge research and development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…